Drugs / axelopran
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01702194 | Nov 2012 → Feb 2013 | opioid-induced constipation | Glycyx Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01655771 | Aug 2012 → Feb 2013 | constipation disorder | Glycyx Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07631325 | Oct 2026 → Jul 2028 expected | cutaneous melanoma | John Kirkwood | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07662720 | Jul 2026 → Aug 2027 expected | head and neck squamous cell carcinoma | Glycyx Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT01040637 | Jan → Oct 2010 | opioid-induced constipation | Glycyx Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07354919 | Apr 2026 → Nov 2027 expected | breast cancer, lung cancer, malignant pancreatic neoplasm, prostate cancer | HealthPartners Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT01459926 | Nov 2011 → May 2012 | opioid-induced constipation | Glycyx Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01401985 | Oct 2011 → May 2012 | opioid-induced constipation | Glycyx Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01333540 | May 2011 → May 2012 | opioid-induced constipation | Glycyx Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01568411 Comparator | Apr → Jun 2012 | — | Glycyx Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-26 | Glycyx Therapeutics | Glycyx Awarded NIH SBIR Phase 2 Grant to Advance Axelopran and Pembrolizumab Study in Head and Neck Cancer glycyx.com ↗ |
| 2024-12-05 | Glycyx Therapeutics | Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It glycyx.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | axelopran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662720 ↗ |
| Known as | AXELOPRAN SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137313 ↗ |
| Known as | TD-1211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01040637 ↗ |
| Known as | TD-1211 Sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137313 ↗ |
| Action | Inhibit | “pharmacologic inhibition of MOR with axelopran” NCT07631325 ↗1“Mu opioid receptor antagonist” CHEMBL3137313 ↗ |
| Modality | Small molecule | — CHEMBL3137313 ↗ |
| Route | Oral | “TD-1211 Administered Orally” NCT01040637 ↗ |
| Target | OPRM1 | “Mu opioid receptor antagonist” CHEMBL3137313 ↗ |